Cynomolgus / Rhesus macaque FcRn / FCGRT&B2M Heterodimer Protein, His Tag (BLI verified)

Proteins and Peptides

貨號 Cat. No.
FCM-C52W9
規格 Size
1mg
品牌 Brand
ACROBiosystems
Species
Cynomolgus / Rhesus macaque
Conjugate
Unconjugated
Expression System
HEK293
Tag
His Tag

Description




Source : 


Cynomolgus / Rhesus macaque FCGRT&B2M Heterodimer Protein, His Tag (BLI verified), is expressed from human 293 cells (HEK293). It contains AA Ala 24 - Ser 297 (FCGRT) & Ile 21 - Met 119 (B2M) (Accession # Q8SPV9-1 (FCGRT) & Q8SPW0-1 (B2M)). In the region Ala 24 - Ser 297 (FCGRT) & Ile 21 - Met 119 (B2M), the AA sequence of Cynomolgus and Rhesus macaque FCGRT&B2M are homologus.


 

Molecule : FcRn (FCGRT & B2M)


 

Synonyms : FcRn,FCGRT & B2M


 

Format : Powder


 

Category : MABSol® Fc Receptors


 

Accession : NP_001271480.1 (FCGRT) & N/A


 

Storage : -20℃


 

Shipping condition : Powder,RT


 

Molecular Weight : 34.1 kDa (FCGRT) & 11.6 kDa (B2M)


 

Characteristics :


Cynomolgus / Rhesus macaque FCGRT&B2M Heterodimer Protein, His Tag (BLI verified), produced by co-expression of FCGRT and B2M, has a calculated MW of 34.1 kDa (FCGRT) and 11.6 kDa (B2M). Subunit FCGRT is fused with a polyhistidine tag at the C-terminus an


 

Endotoxin Level : Less than 1.0 EU per μg by the LAL method.


 

Buffer : PBS, pH7.4


 

Description :


FCGRT & B2M heterodimer protein (FcRn complex) consist of two subunits: p51 (equivalent to FCGRT), and p14 (equivalent to beta-2-microglobulin), and forms an MHC class I-like heterodimer. Fc fragment of IgG, receptor, transporter, alpha (FCGRT) binds to the Fc region of monomeric immunoglobulins gamma and mediates the uptake of IgG from milk. FCGRT possible role in transfer of immunoglobulin G from mother to fetus. Beta-2-microglobulin (B2M) is a component of the class I major histocompatibility complex (MHC) and involved in the presentation of peptide antigens to the immune system.


 

References :


(1) Goebl NA., et al., 2008, Mol. Biol. Cell 19 (12): 5490–505.
(2) Lee TY., et al., 2008, Clin. Cancer Res. 14 (5): 1487–93.
(3) Güssow D., et al., 1987, J. Immunol. 139 (9): 3132–8.
(4) Gorevic P.D., et al., 1986, Proc. Natl. Acad. Sci. U.S.A. 83:7908-7912.





詢價 / 洽詢此產品

同品牌其他產品

回到產品列表

▲ LINE
諮詢